Alembic Pharmaceuticals Limited receives USFDA Final Approval for Levothyroxine Sodium Tablets USP.

Regulatory Product ApprovalBusiness Updates View source PDF

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.2%1-day move

₹749.00

prior close

₹754.85

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.2-0.0+0.5+0.3+1.2+1.3+0.5-2.4-3.3-3.9-1.4+3.7+8.3—

Up moveDown movePending

AI summary

Alembic Pharmaceuticals has received final approval from the USFDA for its Levothyroxine Sodium Tablets USP across 12 dosage strengths (25 mcg to 300 mcg). The product is therapeutically equivalent to AbbVie's branded drug Synthroid and is used for treating hypothyroidism. The US market for this drug is estimated at US$ 1,869 million for the twelve months ending March 2026 according to IQVIA. With this approval, Alembic now holds 239 cumulative ANDA approvals from USFDA (220 final and 19 tentative). Levothyroxine is a commonly prescribed thyroid medication with consistent demand.

Likely market impact

This approval gives Alembic entry into a large US market for thyroid medications, enabling the company to launch a generic version against AbbVie's Synthroid. While it creates a new revenue opportunity, the actual financial impact will depend on market penetration, pricing, and competition in the generic space.